Form 4: HCA Healthcare Director Meg Crofton Receives Stock Award
SEC Form 4 Filing
Director Meg Crofton received 610 shares of HCA Healthcare common stock as part of an annual director equity award.
Summary
- Meg Crofton, a director at HCA Healthcare, Inc., received 610 shares of common stock on April 29, 2024, as part of an annual director equity award.
- These shares are related to restricted share units that will vest on the earlier of the company's 2025 annual shareholders' meeting or the first anniversary of the grant date.
- Vested shares will be delivered upon cessation of board membership.
- Following the transaction, Ms. Crofton directly owns 6,331 shares of HCA Healthcare common stock.
- A Power of Attorney document is included, effective from February 20, 2019, granting authority to John M. Franck II, Natalie Harrison Cline, Kevin A. Ball, and Virginia Chase Crocker to act on Ms. Crofton's behalf regarding SEC filings.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard director compensation practice, indicating alignment of interests between the director and shareholders. There are no apparent negative implications.
Positives
- The receipt of stock indicates continued alignment of the director's interests with those of the shareholders.
- The vesting schedule provides an incentive for continued service on the board.
Future Outlook
The director's vested shares will be delivered upon cessation of board membership.
Industry Context
Stock awards to directors are a common practice in publicly traded companies to incentivize and align their interests with those of shareholders. This Form 4 filing is a routine disclosure required by the SEC.
Comparison to Industry Standards
- Director compensation packages, including stock awards, vary significantly across the healthcare industry.
- Companies like Universal Health Services (UHS) and Tenet Healthcare (THC) also utilize stock awards as part of their director compensation, but the specific amounts and vesting schedules differ based on company size, performance, and governance policies.
- Benchmarking against peer companies would provide a more detailed understanding of the relative value of this award.
Stakeholder Impact
- The stock award aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
- The award does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| February 20, 2019 | Effective date of the Power of Attorney. |
| April 29, 2024 | Date of the stock award transaction. |
| 2025 | Vesting of restricted share units at the annual shareholders' meeting or the first anniversary of the grant date. |
| May 1, 2024 | Date of signature of the filing by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.